Nectar Life Sciences Limited

BSE: 532649 NSE: NECLIFE
Nectar Life Sciences Limited - pharma in Derabassi, Punjab, India. FY 2026 financials and compliance.
CIN L24232PB1995PLC016664 Incorporated 27 June 1995 ROC Chandigarh HQ Derabassi, Punjab, India
Active Listed - NSE: NECLIFE · BSE: 532649 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹0
▼ 100% YoY
EBITDA · FY 2026
-₹51.41 Cr
▼ 109.27% YoY
Net profit · FY 2026
-₹292.89 Cr
▼ 157.64% YoY
Authorised capital
₹35 Cr
Registered with MCA
Paid-up capital
₹22.43 Cr
Issued & subscribed
Open charges
₹60.47 Lakh
Satisfied ₹6,249.44 Cr
Company age
31 yrs
Est. 1995
Employees · EPFO
1,814
Latest available

About Nectar Life Sciences Limited

Data last updated: 18 December 2025

Nectar Life Sciences Limited is a public limited company based in Derabassi, Punjab, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 27 June 1995, the company has been in operation for over 31 years.

Registered with ROC Chandigarh under CIN L24232PB1995PLC016664. Listed on BSE: 532649 and NSE: NECLIFE.

Capital: an authorised share capital of ₹35 Cr and a paid-up capital of ₹22.43 Cr. Formerly known as Surya Medicare Limited. It is led by directors including Rupinder Tewari and Sanjiv Goyal.

Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507.

As per the financials filed for FY 2025, the company reported a revenue of ₹1,674.97 Cr, a decline of 1% compared to the previous year.

The company has a workforce of approximately 1,814 employees as per the latest available data.

The company is associated with 1 brand - Nectar Lifesciences. As per MCA filings, the company has open charges of ₹60.47 Lakh and satisfied charges of ₹6,249.44 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website neclife.com.

Company Details of Nectar Life Sciences Limited
CIN L24232PB1995PLC016664
Registration Number 016664
Incorporation Date 27 June 1995
ROC Chandigarh
Listing Status Listed (BSE: 532649, NSE: NECLIFE)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sanjiv Goyal Managing Director Surulichamy Senthilkumar Whole-Time Director Sushil Kapoor Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    neclife.com
  • Social Media
    **************
  • Registered Address
    Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers
Company report
Nectar Life Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Nectar Life Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Nectar Life Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Nectar Life Sciences Limited

Nectar Life Sciences Limited has one previous CIN (Corporate Identification Number): U24232PB1995PLC016664. The current CIN is L24232PB1995PLC016664, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24232PB1995PLC016664 Current
U24232PB1995PLC016664 Previous

Associated Brands with Nectar Life Sciences Limited

Nectar Life Sciences Limited operates one associated brand: Nectar Lifesciences. These brands represent Nectar Life Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Nectar Lifesciences
Cephalosporin APIs and generic formulations are manufactured. neclife.com

Business Activity of Nectar Life Sciences Limited

Nectar Life Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Nectar Life Sciences Limited

Nectar Life Sciences Limited is audited by Deepak Jindal & Co. (ICAI peer reviewed, certificate valid till 2027-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Deepak Jindal & Co. (ICAI peer reviewed, certificate valid till 2027-05-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Nectar Life Sciences Limited

Nectar Life Sciences Limited is currently managed by 8 directors, with 30 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Rupinder Tewari
Also directs: Nureca Limited
Director 11 Feb 2019 7 Years 4 Months Current
Sanjiv Goyal
Also directs: Nectar Organics Private Limited
Managing Director 27 Jun 1995 31 Years 0 Months Current
Indu Pal Kaur
Also directs: Casanova R&D Private Limited
Director 02 Aug 2022 3 Years 11 Months Current
Kuldip Kumar Bhasin
Also directs: Nureca Limited
Director 21 Sep 2021 4 Years 9 Months Current
Surulichamy Senthilkumar Whole-Time Director 01 Jun 2025 1 Years 1 Months Current
Sushil Kapoor Whole-Time Director 04 Dec 2025 0 Years 7 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Nectar Life Sciences Limited FY 2026 filings available

Nectar Life Sciences Limited reported revenue of ₹- (down 100% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹0 ▼ 100%
Profit · FY 2026
-₹292.89 Cr ▼ 157.64%
EBITDA · FY 2026
-₹51.41 Cr ▼ 109.27%
Revenue₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹2,367 Cr2,367FY 2020FY 2021: ₹1,544 Cr · -34.7% YoY1,544-34.7%FY 2021FY 2022: ₹1,669 Cr · +8.1% YoY1,669+8.1%FY 2022FY 2023: ₹1,525 Cr · -8.6% YoY1,525-8.6%FY 2023FY 2024: ₹1,686 Cr · +10.6% YoY1,686+10.6%FY 2024FY 2025: ₹1,673 Cr · -0.7% YoY1,673-0.7%FY 2025FY 2026: ₹0 Cr · -100% YoY0-100%FY 2026
Net Profit₹ Cr · Consolidated-300-200-1000100FY 2020: ₹32 Cr31.8FY 2020FY 2021: ₹73 Cr (loss) · -330.5% YoY-73.3FY 2021FY 2022: ₹25 Cr · +134.2% YoY25+134.2%FY 2022FY 2023: ₹24 Cr (loss) · -196.6% YoY-24.2FY 2023FY 2024: ₹5 Cr · +120.7% YoY5+120.7%FY 2024FY 2025: ₹114 Cr (loss) · -2376.1% YoY-114FY 2025FY 2026: ₹293 Cr (loss) · -157.6% YoY-293FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0200400600Q1'25: ₹359 Cr · -8.8% YoY359-8.8%Q1'25Q2'25: ₹428 Cr · +7.6% YoY428+7.6%Q2'25Q3'25: ₹455 Cr · +0.6% YoY455+0.6%Q3'25Q4'25: ₹431 Cr · -2.4% YoY431-2.4%Q4'25Q1'26: ₹281 Cr · -21.9% YoY281-21.9%Q1'26Q2'26: ₹5 Cr · -98.8% YoY5-98.8%Q2'26Q3'26: ₹0 Cr · -100% YoY0-100%Q3'26Q4'26: ₹0 Cr · -100% YoY0-100%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹0 ₹1,673.07 Cr ₹1,685.63 Cr ₹1,524.61 Cr ₹1,668.86 Cr ₹1,544.37 Cr ₹2,366.73 Cr
Other Income ₹9.29 Cr ₹1.89 Cr ₹13.03 Cr ₹42.24 Cr ₹11.29 Cr ₹2.72 Cr ₹4.01 Cr
Total Income ₹9.29 Cr ₹1,674.97 Cr ₹1,698.66 Cr ₹1,566.85 Cr ₹1,680.15 Cr ₹1,547.09 Cr ₹2,370.74 Cr
Cost of Materials Consumed ₹0 ₹1,250.72 Cr ₹1,242.45 Cr ₹1,200.84 Cr ₹1,206.88 Cr ₹1,028.4 Cr ₹1,834.03 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹44.02 Lakh ₹24.42 Cr ₹28.8 Cr
Changes in Inventories ₹0 ₹117.29 Cr -₹40.21 Cr -₹41.55 Cr ₹15.81 Cr ₹104.29 Cr -₹4.22 Cr
Employee Benefit Expense ₹1.91 Cr ₹96.47 Cr ₹84.67 Cr ₹77.78 Cr ₹74.55 Cr ₹73.37 Cr ₹81 Cr
Finance Costs ₹36.13 Cr ₹74.58 Cr ₹87.14 Cr ₹79.49 Cr ₹78.81 Cr ₹112.03 Cr ₹125.83 Cr
Depreciation & Amortisation ₹34.26 Lakh ₹62.39 Cr ₹60.72 Cr ₹59.12 Cr ₹56.97 Cr ₹60.25 Cr ₹60.77 Cr
Other Expenses ₹58.79 Cr ₹235.05 Cr ₹245.62 Cr ₹233.6 Cr ₹212.61 Cr ₹203.77 Cr ₹207.07 Cr
Total Expenses ₹97.17 Cr ₹1,836.5 Cr ₹1,680.39 Cr ₹1,609.27 Cr ₹1,646.07 Cr ₹1,606.54 Cr ₹2,333.27 Cr
Profit Before Exceptional Items & Tax -₹87.88 Cr -₹161.53 Cr ₹18.27 Cr -₹42.42 Cr ₹34.08 Cr -₹59.45 Cr ₹37.47 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 -₹25.31 Cr ₹0
Profit Before Tax -₹87.88 Cr -₹161.53 Cr ₹18.27 Cr -₹42.42 Cr ₹34.08 Cr -₹84.77 Cr ₹37.47 Cr
Total Tax Expense -₹30.53 Cr -₹47.85 Cr ₹13.27 Cr -₹18.24 Cr ₹9.03 Cr -₹11.5 Cr ₹5.68 Cr
Net Profit -₹292.89 Cr -₹113.68 Cr ₹4.99 Cr -₹24.18 Cr ₹25.05 Cr -₹73.26 Cr ₹31.79 Cr
  attributable to Owners - - ₹0 ₹0 ₹0 - -
  attributable to NCI - - ₹0 ₹0 ₹0 - -
Other Comprehensive Income ₹7.94 Lakh ₹53.98 Lakh -₹34.13 Lakh ₹87.22 Lakh ₹82.87 Lakh ₹39.85 Lakh ₹52.88 Lakh
Total Comprehensive Income -₹292.81 Cr -₹113.14 Cr ₹4.65 Cr -₹23.31 Cr ₹25.88 Cr -₹72.87 Cr ₹32.32 Cr
EBITDA (computed) -₹51.41 Cr -₹24.57 Cr ₹166.13 Cr ₹96.19 Cr ₹169.86 Cr ₹112.84 Cr ₹224.06 Cr
Basic EPS ₹-2.62 ₹-5.07 ₹0.22 ₹-1.08 ₹1.12 ₹-3.27 ₹1.42
Diluted EPS ₹-2.62 ₹-5.07 ₹0.22 ₹-1.08 ₹1.12 ₹-3.27 ₹1.42
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹621.61 Cr ₹2,047.22 Cr ₹2,191.06 Cr ₹2,189.21 Cr
Non-current Assets ₹332.78 Cr ₹809.64 Cr ₹907.22 Cr ₹958.03 Cr
Current Assets ₹252.97 Cr ₹1,237.59 Cr ₹1,283.83 Cr ₹1,231.18 Cr
Property, Plant & Equipment ₹103.4 Cr ₹576.6 Cr ₹590.31 Cr ₹612.65 Cr
Inventories ₹29.82 Lakh ₹690.16 Cr ₹709.15 Cr ₹672.6 Cr
Trade Receivables ₹0 ₹345.48 Cr ₹379.19 Cr ₹279.61 Cr
Cash & Equivalents ₹0 ₹19.22 Cr ₹19.81 Cr ₹17.58 Cr
Equity (Net Worth) ₹582.3 Cr ₹956.11 Cr ₹1,069.25 Cr ₹1,064.59 Cr
Equity Share Capital ₹19.43 Cr ₹22.43 Cr ₹22.43 Cr ₹22.43 Cr
Borrowings (Non-current) ₹0 ₹60.13 Cr ₹140.31 Cr ₹226.47 Cr
Borrowings (Current) ₹0 ₹521.9 Cr ₹495.23 Cr ₹527.36 Cr
Total Debt (computed) ₹0 ₹582.02 Cr ₹635.54 Cr ₹753.83 Cr
Current Liabilities ₹26.05 Cr ₹1,021.54 Cr ₹972.82 Cr ₹890.93 Cr
Total Liabilities ₹39.31 Cr ₹1,091.12 Cr ₹1,121.81 Cr ₹1,124.62 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹348.72 Cr ₹169.44 Cr ₹224.69 Cr ₹133.65 Cr ₹95.01 Cr
Investing Cash Flow ₹1,208.15 Cr -₹41.93 Cr -₹17.03 Cr ₹51.7 Cr ₹16.64 Cr
Financing Cash Flow -₹766.51 Cr -₹128.09 Cr -₹205.43 Cr -₹185.58 Cr -₹119.38 Cr
Capital Expenditure ₹12.27 Cr ₹43.79 Cr ₹29.42 Cr ₹30.06 Cr ₹24.97 Cr
Free Cash Flow (computed) -₹361 Cr ₹125.64 Cr ₹195.27 Cr ₹103.59 Cr ₹70.04 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹92.91 Cr -₹58.44 Lakh ₹2.23 Cr -₹22.79 Lakh -₹7.73 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹0 ₹0 ₹5 Cr ₹280.67 Cr ₹430.69 Cr ₹454.98 Cr ₹428.1 Cr ₹359.3 Cr ₹441.37 Cr ₹452.17 Cr ₹397.96 Cr ₹394.12 Cr
Other Income ₹7.58 Cr ₹66.08 Lakh ₹74.07 Lakh ₹34.99 Lakh ₹7.77 Lakh ₹57.3 Lakh ₹68.94 Lakh ₹55.08 Lakh ₹1.47 Cr ₹48.02 Lakh ₹10.61 Cr ₹47.31 Lakh
Total Income ₹7.58 Cr ₹66.08 Lakh ₹5.74 Cr ₹281.02 Cr ₹430.77 Cr ₹455.56 Cr ₹428.79 Cr ₹359.85 Cr ₹442.84 Cr ₹452.65 Cr ₹408.57 Cr ₹394.6 Cr
Cost of Materials Consumed ₹0 ₹0 ₹3.41 Cr ₹236.07 Cr ₹405.7 Cr ₹294.15 Cr ₹253.89 Cr ₹296.98 Cr ₹360.32 Cr ₹342.32 Cr ₹256.16 Cr ₹283.65 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹0 ₹0 -₹5.59 Lakh ₹27.47 Cr ₹96.88 Cr ₹37.89 Cr ₹42.16 Cr -₹59.64 Cr -₹52.39 Cr -₹14.96 Cr ₹31.63 Cr -₹4.49 Cr
Employee Benefit Expense ₹1.26 Cr ₹60.95 Lakh ₹75.17 Lakh ₹24.26 Cr ₹23.81 Cr ₹24.5 Cr ₹24.18 Cr ₹23.99 Cr ₹23.94 Cr ₹21.62 Cr ₹20.31 Cr ₹18.8 Cr
Finance Costs ₹5.9 Cr ₹30.22 Cr ₹0 ₹18.7 Cr ₹17.67 Cr ₹17.12 Cr ₹19.81 Cr ₹19.98 Cr ₹24.16 Cr ₹24.84 Cr ₹20.52 Cr ₹17.62 Cr
Depreciation & Amortisation ₹8.28 Lakh ₹6.19 Lakh ₹20.41 Lakh ₹16.52 Cr ₹15.77 Cr ₹15.61 Cr ₹15.55 Cr ₹15.46 Cr ₹14.7 Cr ₹15.37 Cr ₹15.31 Cr ₹15.33 Cr
Other Expenses ₹57.26 Cr ₹1.32 Cr ₹1.93 Cr ₹54.76 Cr ₹58.61 Cr ₹53.73 Cr ₹64.54 Cr ₹58.17 Cr ₹61 Cr ₹60.99 Cr ₹63 Cr ₹60.62 Cr
Total Expenses ₹64.51 Cr ₹32.21 Cr ₹6.24 Cr ₹377.78 Cr ₹618.44 Cr ₹443.01 Cr ₹420.12 Cr ₹354.93 Cr ₹431.73 Cr ₹450.19 Cr ₹406.93 Cr ₹391.54 Cr
Profit Before Exceptional Items & Tax -₹56.93 Cr -₹31.55 Cr -₹50.62 Lakh -₹96.75 Cr -₹187.67 Cr ₹12.55 Cr ₹8.67 Cr ₹4.92 Cr ₹11.11 Cr ₹2.46 Cr ₹1.64 Cr ₹3.06 Cr
Exceptional Items ₹0 ₹88.15 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹56.93 Cr ₹56.6 Cr -₹50.62 Lakh -₹96.75 Cr -₹187.67 Cr ₹12.55 Cr ₹8.67 Cr ₹4.92 Cr ₹11.11 Cr ₹2.46 Cr ₹1.64 Cr ₹3.06 Cr
Total Tax Expense -₹19.72 Cr -₹11.02 Cr -₹17.69 Lakh -₹33.52 Cr -₹57.58 Cr ₹4.71 Cr ₹3.07 Cr ₹1.95 Cr ₹10.52 Cr ₹88.96 Lakh ₹62.62 Lakh ₹1.24 Cr
Net Profit -₹67.92 Cr ₹14.27 Cr -₹176.01 Cr -₹63.23 Cr -₹130.09 Cr ₹7.84 Cr ₹5.6 Cr ₹2.97 Cr ₹59.2 Lakh ₹1.57 Cr ₹1.02 Cr ₹1.82 Cr
  attributable to Owners - - - - - ₹0 - ₹0 ₹0 - - ₹0
  attributable to NCI - - - - - ₹0 - ₹0 ₹0 - - ₹0
Other Comprehensive Income ₹7.93 Lakh ₹0 ₹0 ₹1,000 ₹53.98 Lakh ₹0 ₹0 ₹0 -₹34.13 Lakh ₹0 ₹0 ₹0
Total Comprehensive Income -₹67.84 Cr ₹14.27 Cr -₹176.01 Cr -₹63.23 Cr -₹129.55 Cr ₹7.84 Cr ₹5.6 Cr ₹2.97 Cr ₹25.07 Lakh ₹1.57 Cr ₹1.02 Cr ₹1.82 Cr
EBITDA (computed) -₹50.95 Cr -₹1.26 Cr -₹30.21 Lakh -₹61.54 Cr -₹154.23 Cr ₹45.28 Cr ₹44.02 Cr ₹40.35 Cr ₹49.97 Cr ₹42.67 Cr ₹37.47 Cr ₹36.01 Cr
Basic EPS ₹-1.85 ₹3.02 ₹-0.01 ₹-2.82 ₹-5.80 ₹0.35 ₹0.25 ₹0.13 ₹0.03 ₹0.07 ₹0.05 ₹0.08
Diluted EPS ₹-1.85 ₹3.02 ₹-0.01 ₹-2.82 ₹-5.80 ₹0.35 ₹0.25 ₹0.13 ₹0.03 ₹0.07 ₹0.05 ₹0.08
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2021 FY 2020
Revenue from Operations ₹0 ₹1,673.07 Cr ₹1,685.63 Cr ₹1,524.61 Cr ₹1,542.9 Cr ₹2,363.16 Cr
Other Income ₹9.29 Cr ₹1.89 Cr ₹13.03 Cr ₹42.24 Cr ₹2.72 Cr ₹4.01 Cr
Total Income ₹9.29 Cr ₹1,674.97 Cr ₹1,698.66 Cr ₹1,566.85 Cr ₹1,545.62 Cr ₹2,367.16 Cr
Cost of Materials Consumed ₹0 ₹1,250.72 Cr ₹1,242.45 Cr ₹1,200.84 Cr ₹1,028.4 Cr ₹1,834.03 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹24.42 Cr ₹28.8 Cr
Changes in Inventories ₹0 ₹117.29 Cr -₹40.21 Cr -₹41.64 Cr ₹102.8 Cr -₹5.25 Cr
Employee Benefit Expense ₹1.9 Cr ₹96.47 Cr ₹84.67 Cr ₹77.78 Cr ₹73.37 Cr ₹81 Cr
Finance Costs ₹36.13 Cr ₹74.58 Cr ₹87.14 Cr ₹79.48 Cr ₹112.03 Cr ₹125.82 Cr
Depreciation & Amortisation ₹34.26 Lakh ₹62.39 Cr ₹60.72 Cr ₹59.12 Cr ₹60.25 Cr ₹60.77 Cr
Other Expenses ₹58.79 Cr ₹235.05 Cr ₹245.61 Cr ₹231.97 Cr ₹203.68 Cr ₹206.25 Cr
Total Expenses ₹97.16 Cr ₹1,836.5 Cr ₹1,680.39 Cr ₹1,607.54 Cr ₹1,604.95 Cr ₹2,331.42 Cr
Profit Before Exceptional Items & Tax -₹87.87 Cr -₹161.53 Cr ₹18.28 Cr -₹40.69 Cr -₹59.34 Cr ₹35.74 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 -₹25.31 Cr ₹0
Profit Before Tax -₹87.87 Cr -₹161.53 Cr ₹18.28 Cr -₹40.69 Cr -₹84.65 Cr ₹35.74 Cr
Total Tax Expense -₹30.53 Cr -₹47.85 Cr ₹13.27 Cr -₹18.24 Cr -₹11.5 Cr ₹5.68 Cr
Net Profit -₹292.88 Cr -₹113.68 Cr ₹5 Cr -₹22.46 Cr -₹73.15 Cr ₹30.06 Cr
Other Comprehensive Income ₹7.92 Lakh ₹53.98 Lakh -₹34.19 Lakh ₹18.78 Lakh ₹39.36 Lakh ₹1.26 Cr
Total Comprehensive Income -₹292.81 Cr -₹113.14 Cr ₹4.66 Cr -₹22.27 Cr -₹72.75 Cr ₹31.32 Cr
EBITDA (computed) -₹51.4 Cr -₹24.57 Cr ₹166.14 Cr ₹97.9 Cr ₹112.95 Cr ₹222.33 Cr
Basic EPS ₹-2.62 ₹-5.07 ₹0.22 ₹-1.00 ₹-3.26 ₹1.34
Diluted EPS ₹-2.62 ₹-5.07 ₹0.22 ₹-1.00 ₹-3.26 ₹1.34
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹612.34 Cr ₹2,047.23 Cr ₹2,191.06 Cr ₹2,189.21 Cr
Non-current Assets ₹326.92 Cr ₹809.65 Cr ₹907.23 Cr ₹958.04 Cr
Current Assets ₹249.57 Cr ₹1,237.59 Cr ₹1,283.83 Cr ₹1,231.18 Cr
Property, Plant & Equipment ₹3.45 Cr ₹576.6 Cr ₹590.31 Cr ₹612.65 Cr
Inventories ₹29.82 Lakh ₹690.16 Cr ₹709.15 Cr ₹672.6 Cr
Trade Receivables ₹0 ₹345.48 Cr ₹379.19 Cr ₹279.61 Cr
Cash & Equivalents ₹0 ₹19.22 Cr ₹19.8 Cr ₹17.57 Cr
Equity (Net Worth) ₹582.31 Cr ₹956.11 Cr ₹1,069.25 Cr ₹1,064.59 Cr
Equity Share Capital ₹19.43 Cr ₹22.43 Cr ₹22.43 Cr ₹22.43 Cr
Borrowings (Non-current) ₹0 ₹60.13 Cr ₹140.31 Cr ₹226.47 Cr
Borrowings (Current) ₹0 ₹521.9 Cr ₹495.23 Cr ₹527.36 Cr
Total Debt (computed) ₹0 ₹582.02 Cr ₹635.54 Cr ₹753.83 Cr
Current Liabilities ₹25.97 Cr ₹1,021.54 Cr ₹972.82 Cr ₹890.93 Cr
Total Liabilities ₹30.04 Cr ₹1,091.12 Cr ₹1,121.81 Cr ₹1,124.62 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Operating Cash Flow -₹417.35 Cr ₹169.44 Cr ₹224.69 Cr ₹133.37 Cr
Investing Cash Flow ₹1,205.41 Cr -₹41.93 Cr -₹17.03 Cr ₹52.03 Cr
Financing Cash Flow -₹699.15 Cr -₹128.09 Cr -₹205.43 Cr -₹185.57 Cr
Capital Expenditure ₹11.53 Cr ₹43.79 Cr ₹29.42 Cr ₹30.06 Cr
Free Cash Flow (computed) -₹428.88 Cr ₹125.64 Cr ₹195.28 Cr ₹103.31 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹88.91 Cr -₹58.45 Lakh ₹2.23 Cr -₹16.66 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹0 ₹0 ₹5 Cr ₹280.67 Cr ₹430.69 Cr ₹454.98 Cr ₹428.1 Cr ₹359.3 Cr ₹441.37 Cr ₹452.17 Cr ₹397.96 Cr ₹394.12 Cr
Other Income ₹7.58 Cr ₹66.08 Lakh ₹74.07 Lakh ₹34.99 Lakh ₹7.77 Lakh ₹57.3 Lakh ₹68.94 Lakh ₹55.08 Lakh ₹1.47 Cr ₹48.02 Lakh ₹10.61 Cr ₹47.31 Lakh
Total Income ₹7.58 Cr ₹66.08 Lakh ₹5.74 Cr ₹281.02 Cr ₹430.77 Cr ₹455.56 Cr ₹428.79 Cr ₹359.85 Cr ₹442.84 Cr ₹452.65 Cr ₹408.57 Cr ₹394.6 Cr
Cost of Materials Consumed ₹0 ₹0 ₹3.41 Cr ₹236.07 Cr ₹405.7 Cr ₹294.15 Cr ₹253.89 Cr ₹296.98 Cr ₹360.32 Cr ₹342.32 Cr ₹256.16 Cr ₹283.65 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹0 ₹0 -₹5.59 Lakh ₹27.47 Cr ₹96.88 Cr ₹37.89 Cr ₹42.16 Cr -₹59.64 Cr -₹52.39 Cr -₹14.96 Cr ₹31.63 Cr -₹4.49 Cr
Employee Benefit Expense ₹1.25 Cr ₹60.95 Lakh ₹75.17 Lakh ₹24.26 Cr ₹23.81 Cr ₹24.5 Cr ₹24.18 Cr ₹23.99 Cr ₹23.94 Cr ₹21.62 Cr ₹20.31 Cr ₹18.8 Cr
Finance Costs ₹5.9 Cr ₹30.22 Cr ₹0 ₹18.7 Cr ₹17.67 Cr ₹17.12 Cr ₹19.81 Cr ₹19.98 Cr ₹24.16 Cr ₹24.84 Cr ₹20.52 Cr ₹17.62 Cr
Depreciation & Amortisation ₹8.28 Lakh ₹6.19 Lakh ₹20.41 Lakh ₹16.52 Cr ₹15.77 Cr ₹15.61 Cr ₹15.55 Cr ₹15.46 Cr ₹14.7 Cr ₹15.37 Cr ₹15.31 Cr ₹15.33 Cr
Other Expenses ₹57.26 Cr ₹1.32 Cr ₹1.93 Cr ₹54.76 Cr ₹58.61 Cr ₹53.73 Cr ₹64.54 Cr ₹58.17 Cr ₹61 Cr ₹60.99 Cr ₹63 Cr ₹60.62 Cr
Total Expenses ₹64.5 Cr ₹32.21 Cr ₹6.24 Cr ₹377.78 Cr ₹618.44 Cr ₹443.01 Cr ₹420.12 Cr ₹354.93 Cr ₹431.72 Cr ₹450.19 Cr ₹406.93 Cr ₹391.54 Cr
Profit Before Exceptional Items & Tax -₹56.92 Cr -₹31.55 Cr -₹50.62 Lakh -₹96.75 Cr -₹187.67 Cr ₹12.55 Cr ₹8.67 Cr ₹4.92 Cr ₹11.12 Cr ₹2.46 Cr ₹1.64 Cr ₹3.06 Cr
Exceptional Items ₹0 ₹88.15 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹56.92 Cr ₹56.6 Cr -₹50.62 Lakh -₹96.75 Cr -₹187.67 Cr ₹12.55 Cr ₹8.67 Cr ₹4.92 Cr ₹11.12 Cr ₹2.46 Cr ₹1.64 Cr ₹3.06 Cr
Total Tax Expense -₹19.71 Cr -₹11.02 Cr -₹17.69 Lakh -₹33.52 Cr -₹57.58 Cr ₹4.71 Cr ₹3.07 Cr ₹1.95 Cr ₹10.52 Cr ₹88.96 Lakh ₹62.62 Lakh ₹1.24 Cr
Net Profit -₹67.92 Cr ₹14.27 Cr -₹176.01 Cr -₹63.23 Cr -₹130.09 Cr ₹7.84 Cr ₹5.6 Cr ₹2.97 Cr ₹59.91 Lakh ₹1.57 Cr ₹1.02 Cr ₹1.82 Cr
Other Comprehensive Income ₹7.92 Lakh ₹0 ₹0 ₹0 ₹53.98 Lakh ₹0 ₹0 ₹0 -₹34.19 Lakh ₹0 ₹0 ₹0
Total Comprehensive Income -₹67.84 Cr ₹14.27 Cr -₹176.01 Cr -₹63.23 Cr -₹129.55 Cr ₹7.84 Cr ₹5.6 Cr ₹2.97 Cr ₹25.72 Lakh ₹1.57 Cr ₹1.02 Cr ₹1.82 Cr
EBITDA (computed) -₹50.94 Cr -₹1.26 Cr -₹30.21 Lakh -₹61.54 Cr -₹154.23 Cr ₹45.28 Cr ₹44.02 Cr ₹40.35 Cr ₹49.98 Cr ₹42.67 Cr ₹37.47 Cr ₹36.01 Cr
Basic EPS ₹-1.85 ₹3.02 ₹-0.01 ₹-2.82 ₹-5.80 ₹0.35 ₹0.25 ₹0.13 ₹0.03 ₹0.07 ₹0.05 ₹0.08
Diluted EPS ₹-1.85 ₹3.02 ₹-0.01 ₹-2.82 ₹-5.80 ₹0.35 ₹0.25 ₹0.13 ₹0.03 ₹0.07 ₹0.05 ₹0.08
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Nectar Life Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Nectar Life Sciences Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 51.84%, foreign institutional investors hold 0.60%, domestic institutional investors hold 4.01%, retail and other public shareholders hold 43.52% of Nectar Life Sciences Limited. The company had 74,834 shareholders on record.

Promoters: 51.84%DII (Domestic Institutional): 4.01%FII (Foreign Institutional): 0.60%Retail & Others: 43.52%
Mar 2026
QUARTER
51.84% Promoters
4.01% DII (Domestic Institutional)
0.60% FII (Foreign Institutional)
43.52% Retail & Others
Promoter holding - history
Now 51.84% · Mar 2026High 55.80% · Dec 2015Low 44.53% · Dec 2024
43%46.5%50%53.5%57%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 55.80%Mar 2016: 55.80%Jun 2016: 55.80%Sep 2016: 55.80%Dec 2016: 55.80%Mar 2017: 55.80%Jun 2017: 55.80%Sep 2017: 55.80%Dec 2017: 55.80%Mar 2018: 55.80%Jun 2018: 55.80%Sep 2018: 55.80%Dec 2018: 55.80%Mar 2019: 55.80%Jun 2019: 55.80%Sep 2019: 55.80%Dec 2019: 55.80%Mar 2020: 55.80%Jun 2020: 55.80%Sep 2020: 55.80%Dec 2020: 55.80%Mar 2021: 55.80%Jun 2021: 55.80%Sep 2021: 55.80%Dec 2021: 55.80%Mar 2022: 55.80%Jun 2022: 55.80%Sep 2022: 55.80%Dec 2022: 55.80%Mar 2023: 55.80%Jun 2023: 55.80%Sep 2023: 55.80%Dec 2023: 55.80%Mar 2024: 55.80%Jun 2024: 55.80%Sep 2024: 55.80%Dec 2024: 44.53%Mar 2025: 44.53%Jun 2025: 44.53%Sep 2025: 44.91%Dec 2025: 44.91%Jan 2026: 51.84%Mar 2026: 51.84%55.80%44.53%51.84%
Shareholding trend - last 6 quarters
Mar 2026Jan 2026Dec 2025Sep 2025Jun 2025Mar 2025
Promoters51.84%51.84%44.91%44.91%44.53%44.53%
Public48.16%48.16%55.09%55.09%55.47%55.47%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters51.84%44.53%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%
Public48.16%55.47%44.20%44.20%44.20%44.20%44.20%44.20%44.20%44.20%44.20%
Promoter change (YoY, %pts)+7.31-11.27+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00-

Board & Governance of Nectar Life Sciences Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Nectar Life Sciences Limited has 6 directors - 3 independent and 2 executive. The board is chaired by SANJIV GOYAL.

DirectorPositionOn board sinceListed boards
SANJIV GOYAL Executive Director · MD · Chairperson 1995-06-27 1
RUPINDER TEWARI Non-Executive - Independent Director 2019-02-11 2
KULDIP KUMAR BHASIN Non-Executive - Independent Director 2021-09-21 2
INDU PAL KAUR Non-Executive - Independent Director 2022-08-02 1
SURULICHAMY SENTHILKUMAR Non-Executive - Non Independent Director 2025-06-01 1
SUSHIL KAPOOR Executive Director 2025-12-04 1
Board Committees
CommitteeMembers
Audit Committee RUPINDER TEWARI (Chairperson), KULDIP KUMAR BHASIN, INDU PAL KAUR, SANJIV GOYAL
Nomination and remuneration committee RUPINDER TEWARI (Chairperson), KULDIP KUMAR BHASIN, INDU PAL KAUR
Stakeholders Relationship Committee KULDIP KUMAR BHASIN (Chairperson), SANJIV GOYAL, SURULICHAMY SENTHILKUMAR
Risk Management Committee SANJIV GOYAL (Chairperson), RUPINDER TEWARI, SUSHIL KAPOOR
Corporate Social Responsibility Committee SANJIV GOYAL (Chairperson), KULDIP KUMAR BHASIN, SURULICHAMY SENTHILKUMAR
MANAGEMENT COMMITTEE SANJIV GOYAL (Chairperson), SURULICHAMY SENTHILKUMAR, SUSHIL KAPOOR

Charges & Borrowings of Nectar Life Sciences Limited

Open charges
₹60.47 Lakh
Satisfied charges
₹6,249.44 Cr
Breakdown by lending institutions
Others₹1,377.64 Cr
Sbicap Trustee Company Limited₹1,338.35 Cr
Punjab National Bank₹790.10 Cr
State Bank of India₹771.01 Cr
Export-Import Bank of India₹430.00 Cr
Others₹1,542.33 Cr
Latest charge details
DateLenderAmountStatus
27 Dec 2023 Hdfc Bank Limited ₹60.47 Lakh Satisfied
28 Jun 2022 Hdfc Bank Limited ₹20 Lakh Satisfied
01 Dec 2021 Hdfc Bank Limited ₹20 Lakh Satisfied
14 Jul 2021 Hdfc Bank Limited ₹6 Lakh Satisfied
21 Jun 2021 Sbicap Trustee Company Limited ₹1,338.35 Cr Satisfied

Total charge records: 111 View all charges

Employees and EPFO Compliance at Nectar Life Sciences Limited

Nectar Life Sciences Limited has a workforce of 1,814 employees as of Nov 28, 2025.

Employee count
1,814
Active EPFO establishments
4
Employee growth
0.39%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Nectar Life Sciences Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Nectar Life Sciences Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Nectar Life Sciences Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Nectar Life Sciences Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Nectar Life Sciences Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Nectar Life Sciences Limited

MSME Payment Delays by Nectar Life Sciences Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Nectar Life Sciences Limited

Subsidiaries & Group Companies of Nectar Life Sciences Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Nectar Life Sciences Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Nectar Life Sciences Limited

MCA Filings & Documents of Nectar Life Sciences Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Nectar Life Sciences Limited

Directors
04 Dec 2025
Sushil Kapoor was appointed as a Whole-Time Director on 04 Dec 2025 & has been associated with this company since 7 months 5 days.
Charges
14 Nov 2025
A charge registered on 27 Dec 2023 via Charge ID 100841946 with Hdfc Bank Limited was fully satisfied on 14 Nov 2025.
Charges
21 Oct 2025
A charge registered on 21 Jun 2021 via Charge ID 100458233 with Sbicap Trustee Company Limited was fully satisfied on 21 Oct 2025.
Activity
29 Sep 2025
Nectar Life Sciences Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
01 Aug 2025
A charge registered on 28 Jun 2022 via Charge ID 100593892 with Hdfc Bank Limited was fully satisfied on 01 Aug 2025.
Charges
03 Jul 2025
A charge registered on 01 Dec 2021 via Charge ID 100511693 with Hdfc Bank Limited was fully satisfied on 03 Jul 2025.

Recent News on Nectar Life Sciences Limited

Frequently Asked Questions about Nectar Life Sciences Limited

Nectar Life Sciences Limited is an active public limited company in the pharma sector based in Derabassi, Punjab, India. It was incorporated on 27 June 1995 (31+ years old) and is registered under CIN L24232PB1995PLC016664. Listed on BSE: 532649 and NSE: NECLIFE. The company has 1,814 employees.

Nectar Life Sciences Limited reported revenue of ₹1,674.97 Cr for FY 2025 (down 1.00% YoY).

The current directors of Nectar Life Sciences Limited are:

The primary industry of Nectar Life Sciences Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Nectar Life Sciences Limited is listed on both BSE (code: 532649) and NSE (symbol: NECLIFE).

Nectar Life Sciences Limited can be reached at the registered office: Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507, or through the website neclife.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available